More @OncoAlert weekly RoundUp. This is the #1 method I use to keep up to date across tumor types (and @OncBrothers to be fair). monarchE with some expected data. Immunotherapy marches on, now in HR+ breast cancer. Some GI studies to round things out (screening works, and.

Despite its rising incidence 📈 and poor outcomes, we still have a limited understanding of the biology driving early-onset colorectal cancer (<50y). Most prior studies were small, inconsistent, or confounded by MSI and treatment exposure. In JCO OA, Futreal, @skopetz , and.

Join millions who have switched to Grok.

It’s happening again!.GI-ASCO #26 registrations are open!.

Feel like I’ve felt this way before. @TheGutOncLab @UGrewalMD @Deebacca @TimothyJBrownMD

OncoAlert coming in again this week with a compact roundup. Amplify201 with JRAS vaccine in panc and CRC. Many other great studies.

RT @TheGutOncLab: Excited to have the one and only @NiuSanford join us for our lab meeting today. Exciting perspectives on some very cool G….

@pashtoonkasi.

Hot off the presses, probably my favorite interventional paper of 2025 (doesn't hurt that I look up to several of the authors as mentors or role models). 💉RAS vaccination is starting to look less like fantasy, more like reality. 🆕 Nature Medicine | Wainberg et al.🎯

Another week, another great summary spanning across every cancer types!. 📲 Register: Melanoma, Breast, Pancreas; it's all covered! . Do wonder where the discussion of the Elicio KRAS peptide vaccine is (maybe next week). @OncoAlert.

RT @manjuggm: Thank you for shining the light of attention on cancer #patientadvocacy! Honored to be in this group!. @paltown1 @UMMC_Cancer….

I feel seen

CEA was discovered in 1965. By the 1970s, CEACAM5 was recognized as a hallmark of colorectal cancer. Yet in 2025, CRC still has no approved ADCs. That may change. 🚨 First-in-human data for Precem-TcT (anti-CEACAM5 + exatecan) now in Nature Medicine. PROCEADE-CRC-01 dose.

The lab delivers!.

OncoAlert out again this week helping me stay updated across a variety of tumor types!. Lung once leading the pack (still jealous they get all the drugs first); some interesting studies coming out for prostate and breast as well. @OncoAlert.

Are you, like me, starting to get overwhelmed with the wealth of options in upper GI? .HER2.PDL1.MSI-H.CLDN18.2.(Now FGFR2).Well, @UGrewalMD and @TimothyJBrownMD have a great review article piecing it all together. Next goal. Get one person on tumor board to stop recommending

As we’ve launched a new HAI program in Manhattan at Northwell, questions around optimal dosing strategies are front and center. This new @cityofhope study asks: can we de-escalate initial FUDR dosing and still preserve outcomes in adjuvant HAI?. Retrospective and single-center —.

Another new paper out! Grateful to have been a part of the effort. We (Andrew Pellatt and Arvind Dasari) asked: Can TAS-102 eliminate ctDNA-defined MRD in CRC after adjuvant chemo?. 💊 Single-arm phase II study of CRC pts with MRD by ctDNA after curative-intent therapy (Stage.

💥New paper out!.We reanalyzed raw sequencing data from 18,558 standard-of-care Guardant360 ctDNA assays in advanced #colorectalcancer using a partner-agnostic fusion caller. 🧬 Fusions in 1.3% of patients.🧪 93% were subclonal — enriched after EGFR therapy.🔗 Clonal fusions.

So much good science! .Gut Onc Lab should be well represented at GI-ASCO. Really excited for some of the things we’re working on as they’re progressing from concept, to data and now publication.

Lots of great discussion in this weeks RoundUp!. I’ve never been the biggest fan of PARPi in bio-marked unselected patients, but I guess that is where the field is heading. ACCORD with some interesting results… Is it the Carmelizumab (PD1) or the RT driving the show? Not sure,.